Two pediatric deaths in Chinese CRISPR trials reignite debate over AAV delivery risks, as many of the 15 genetic-medicine ...
Lilly's 13 acquisitions in 2026, worth about $32B, are recycling cash back to at least 50 biotech venture investors.
Trump strikes MFN drug-pricing deals with 9 more drugmakers as Incyte joins quietly; Oz says 600K seniors signed up for CMS ...
Google's Gemini now lets users book appointments via Zocdoc. Google Health Chief Michael Howell and Zocdoc CEO Oliver Kharraz ...
Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward ...
Roche licenses Simcere Zaiming's preclinical trispecific T cell engager SIM0660 for $75M upfront, up to $1.53B in biobucks, its second China biotech deal this month.
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
Eli Lilly acquires Merida Biosciences for up to $2.875B, gaining MER511 for thyroid eye disease/Graves' disease and MER769 ...
Sanofi-backed Electra files for a Nasdaq IPO to fund Phase 2/3 trials of ipsoprubart, its lead antibody for the rare disease ...
ARCH Venture Partners is targeting $3B for its 14th fund, per an SEC filing, matching the size of the fund it disclosed in ...
After lengthy consideration, a DC federal judge on Monday rejected Merck’s challenge to Medicare drug price ...
Nine more drugmakers strike voluntary drug-pricing deals with the White House, pledging nearly $20B in US investments to avoid tariffs and CMS pricing pilots.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results